Cerebral Vasospasm Market Research Report- Forecast to 2027

Cerebral Vasospasm Market Research Report, by Diagnosis (Computed Tomography Angiography, Digital Subtraction Angiography), Treatment (Nimodipine, Triple-H Therapy, Balloon Angioplasty), End-User (Hospitals, Clinics)– Global Forecast Till 2027

ID: MRFR/MED/0909-HCR | February 2021 | Region: Global | 85 Pages         

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Cerebral Vasospasm Market, by Diagnosis

6.1 Introduction

6.2 CT scan

6.3 Computed Tomography Angiography (CTA)

6.4 Digital Subtraction Angiography (DSA)

6.5 Magnetic Resonance Angiography (MRA)

6.6 Transcranial Doppler (TCD)

Chapter 7. Global Cerebral Vasospasm Market, by Treatment

7.1 Introduction

7.2 Nimodipine

7.3 Triple-H therapy

7.4 Balloon Angioplasty

7.5 Vasopressors

7.6 Inotropes

7.7 Thrombolytic Agents

7.8 Anti-inflammatory Agents

Chapter 8. Global Cerebral Vasospasm Market, by End-Users

8.1 Introduction

8.2 Hospitals and Clinics

8.3 Ambulatory Surgical Centers

8.4 Trauma Centers

8.5 Emergency Departments

8.6 Others

Chapter 9. Global Cerebral Vasospasm Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Headsense Medical Ltd

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 B. Braun Melsungen AG

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Minnetronix, Inc

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bristol-Myers Squibb Company

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Boehringer Ingelheim GmbH

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 H. Lundbeck A/S

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Koninklijke Philips N.V

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 SIEMENS AG

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Edge Therapeutics, Inc.

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 GE Healthcare

11.10.1 Overview

11.10.2 Type Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Actelion Pharmaceuticals Ltd.

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Global Cerebral Vasospasm Market Industry Synopsis, 2020-2027

Table 2 Global Cerebral Vasospasm Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Global Cerebral Vasospasm Market, by Region, 2020-2027, (USD Million)

Table 4 Global Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 6 Global Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

Table 7 North America: Prescribed Health Apps Market, by Diagnosis, 2020-2027, (USD Million)

Table 8 North America: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 9 North America: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

Table 10 US: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

Table 11 US: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 12 US: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

Table 13 Canada: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 15 Canada: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

Table 16 South America: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

Table 17 South America: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 18 South America: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

Table 19 Europe: Cerebral Vasospasm Market, Diagnosis, 2020-2027, (USD Million)

Table 20 Europe: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 21 Europe: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

Table 22 Western Europe: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

Table 25 Eastern Europe: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

Table 28 Asia-Pacific: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia-Pacific: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 30 Asia-Pacific: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

Table 31 Middle East & Africa: Cerebral Vasospasm Market, by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa: Cerebral Vasospasm Market, by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa: Cerebral Vasospasm Market, by End-User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Cerebral Vasospasm Market

Figure 3 Market Dynamics for the Global Cerebral Vasospasm Market

Figure 4 Global Cerebral Vasospasm Market Share, by Diagnosis 2020

Figure 6 Global Cerebral Vasospasm Market Share, by Treatment, 2020

Figure 6 Global Cerebral Vasospasm Market Share, by End-User, 2020

Figure 7 Global Cerebral Vasospasm Market Share, by Region, 2020

Figure 8 North America Cerebral Vasospasm Market Share, by Country, 2020

Figure 9 Europe Prescribed Health Apps Share, by Country, 2020

Figure 10 Asia-Pacific Cerebral Vasospasm Market Share, by Country, 2020

Figure 11 Middle East & Africa Cerebral Vasospasm Market Share, by Country, 2020

Figure 12 Global Cerebral Vasospasm Market: Company Share Analysis, 2020 (%)

Figure 13 Headsense Medical Ltd: Key Financials

Figure 14 Headsense Medical Ltd: Segmental Revenue

Figure 15 Headsense Medical Ltd: Geographical Revenue

Figure 16 B. Braun Melsungen AG: Key Financials

Figure 17 B. Braun Melsungen AG: Segmental Revenue

Figure 18 B. Braun Melsungen AG: Geographical Revenue

Figure 19 Minnetronix, Inc: Key Financials

Figure 20 Minnetronix, Inc: Segmental Revenue

Figure 21 Minnetronix, Inc: Geographical Revenue

Figure 22 Bristol-Myers Squibb Company: Key Financials

Figure 23 Bristol-Myers Squibb Company: Segmental Revenue

Figure 24 Bristol-Myers Squibb Company: Geographical Revenue

Figure 25 Boehringer Ingelheim GmbH: Key Financials

Figure 26 Boehringer Ingelheim GmbH: Segmental Revenue

Figure 27 Boehringer Ingelheim GmbH: Geographical Revenue

Figure 28 H. Lundbeck A/S: Key Financials

Figure 29 H. Lundbeck A/S: Segmental Revenue

Figure 30 H. Lundbeck A/S: Geographical Revenue

Figure 31 Koninklijke Philips N.V: Key Financials

Figure 32 Koninklijke Philips N.V: Segmental Revenue

Figure 33 Koninklijke Philips N.V: Geographical Revenue

Figure 34 SIEMENS AG: Key Financials

Figure 35 SIEMENS AG: Segmental Revenue

Figure 36 SIEMENS AG: Geographical Revenue

Figure 37 Edge Therapeutics, Inc.: Key Financials

Figure 38 Edge Therapeutics, Inc.: Segmental Revenue

Figure 39 Edge Therapeutics, Inc.: Geographical Revenue

Figure 40 GE Healthcare: Key Financials

Figure 41 GE Healthcare: Segmental Revenue

Figure 42 GE Healthcare: Geographical Revenue

Figure 43 Actelion Pharmaceuticals Ltd.: Key Financials

Figure 44 Actelion Pharmaceuticals Ltd.: Segmental Revenue

Figure 45 Actelion Pharmaceuticals Ltd.: Geographical Revenue

Cerebral Vasospasm Market Speak to Analyst Request a Free Sample

Cerebral Vasospasm Market Overview


The cerebral vasospasm market share is expected register at a CAGR of 5.4% during the forecast period. Cerebral vasospasm usually is the narrowing of cerebral arteries. Patients who survive a subarachnoid hemorrhage are more likely to experience cerebral vasospasm. A narrowing of the cerebral artery causes cerebral ischemia, which leads to death. Vasospasm of the bigger conducting arteries in the subarachnoid region, which is initially covered by a clot, is known as cerebral vasospasm. This type of hemorrhagic stroke can result in severe cerebral vasospasm, which causes entire brain areas to become blood-deprived in the days following the stroke, resulting in serious repercussions. Over the first few days after an aneurysmal rupture, significant constriction of the blood arteries in the brain occurs. Following an intracerebral hemorrhage, this type of constriction usually peaks in about a week.


Symptoms usually appear 3 to 14 days after the original subarachnoid hemorrhage, but it can happen up to 3 weeks later, with the highest risk at 7 days. A physician may utilize transcranial dopplers, CT-angiography, MR-angiography, or a cerebral angiogram to identify cerebral vasospasm. Although the disease's exact cause is unknown, it is assumed to be caused by a chemical imbalance that causes vasoconstriction and vasodilation. The majority of patients with subarachnoid hemorrhages are given medications to avoid cerebral vasospasm-related strokes. Once the condition has been identified, treatment options include raising blood pressure to force blood flow to the brain and/or angiography. Angiography allows a physician to send medicine to the arteries and/or dilate them with balloon angioplasty, depending on the severity and location of the vasospasm.


COVID-19 Analysis


Bottlenecks have formed in industry pipelines, sales funnels, and supply chain activities as a result of the COVID-19 Pandemic. COVID-19's global proliferation has posed a significant socioeconomic cost and has become a major global public health hazard. The COVID-19 older population is in danger, especially those with hypertension, diabetes, cardiovascular, and cerebral vasospasm illnesses which will lead to Cerebral Vasospasm Market Growth. If infected with COVID-19, these people have the highest mortality rates. Even though the lungs are the primary organs engaged in COVID-19-induced acute respiratory distress syndrome. It activates inflammatory and immunological systems, resulting in a cytokine storm that accelerates illness development and may lead to death. According to present research, new coronavirus does not improve the prognosis of patients with cerebral vasospasm illnesses, and changes in their clinical condition should be closely monitored.


COVID-19 has the potential to cause respiratory problems as well as other main and secondary nervous system problems. Acute Cerebral Vasospasm Market Analysis such as sudden speech confusion and limb paralysis have been reported in COVID-19 patients; symptoms of intracranial infection such as headache, epilepsy, and disturbance of consciousness; symptoms of muscle damage such as soreness and weakness of limbs; and occasionally symptoms such as neuralgia, abnormal sensation. During this time of high COVID-19 prevalence, neurologists should give extra attention to this patient population, particularly those with nervous system symptoms. COVID-19 may stymie the Cerebral Vasospasm Market Trends.


Cerebral Vasospasm Market Dynamics


Drivers


The market for cerebral vasospasm is expanding as the frequency of traumatic brain injuries rises. The primary factor driving the Cerebral Vasospasm Market Size is an increase in the prevalence of subarachnoid hemorrhage and a rise in the prevalence of traumatic brain injury. Increased hypertension in the population, increased smoking adoption, changing lifestyle, growing geriatric population, rising prevalence of bleeding disorders, rising usage of blood thinners, and the development of technologically enhanced treatments are all contributing to the Cerebral Vasospasm Market Growth.


Restraints


The high expense of therapy and rising worries about the hazards connected with pharmaceuticals and therapies are projected to stymie the Market Value. The market is expected to face challenges due to a scarcity of qualified specialists.


The market analysis for each country, including growth in healthcare capital expenditure, installed base of various types of products for the market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market. The technology interacts with some nerves from within the arteries in the lower brain to release arterial constriction throughout the brain using a less invasive electroactive endovascular probe. The technology has helped in increasing Cerebral Vasospasm Market Size.


Cerebral Vasospasm Market Segment Overview


The Cerebral Vasospasm Market Share has been bifurcated into various segments that will help the market to achieve the highest CAGR during the Forecast period.


Based on the diagnosis, market is segmented as follows:



  • CT Scan

  • Computed Tomography Angiography (CTA)

  • Digital Subtraction Angiography (DSA)

  • Magnetic Resonance Angiography (MRA)

  • Transcranial Doppler (TCD)

  •  


Based on the treatment segment, the market is segmented as follows:



  • Nimodipine

  • Triple-h Therapy

  • Balloon Angioplasty

  • Vasopressors

  • Inotropes

  • Thrombolytic Agents

  • Anti-inflammatory Agents


Based on the end-users, the market is segmented as follows:



  • Hospitals and Clinics

  • Ambulatory Surgical Centers

  • Trauma Centers

  • Emergency Departments

  • Others


Based on the region, the market is segmented as follows:



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East and Africa


Cerebral Vasospasm Market Regional Classification


Because of the rising number of traumatic brain injuries in this region, North America dominates the cerebral vasospasm market. The increased prevalence of brain traumatic injuries has an impact on market growth. Furthermore, rising healthcare expenditures and increased acceptance of technologically advanced medical implants are helping to drive Market Value in this area.


Europe is thought to be the second-largest market for cerebral vasospasm treatment. The market in this region is being driven by the rising health burden caused by smoking. During the historic projection period, 484,700 persons were hospitalized owing to health complications related to smoking. This creates excellent conditions for the Cerebral Vasospasm Market Outlook to expand in this area.


In Asia-Pacific, because of the rising number of senior people, the  market is expected to develop during the Forecast. Aneurysms in the brain develop after the age of 40 and are common in the older population. Asia's geriatric population is predicted to reach 923 million by 2050, according to the Asian Development Bank (ADB). This contributes to the region's healthy market growth.


Due to strict government rules and underdeveloped economies, the Middle East and Africa have the smallest share in the cerebral vasospasm market. Growing government initiatives, private sector investments, and well-equipped healthcare facilities, on the other hand, are expected to boost market expansion in this region.


Cerebral Vasospasm Market Competitive Landscape


The competitive landscape for the cerebral vasospasm market is broken down by competitors. Company overview, financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites, and facilities are all covered in the information. The major key players of the market are Headsense Medical Ltd (Israel), B. Braun Melsungen AG (Germany), Minnetronix, Inc (US), Bristol-Myers Squibb Company (US), Boehringer Ingelheim GmbH (Germany), H. Lundbeck A/S (Denmark), Actelion Pharmaceuticals Ltd, GE Healthcare, Edge Therapeutics, Inc, SIEMENS AG, Artiria Medical (Switzerland), Koninklijke Philips N.V, and others.


Recent Developments


The Wyss Center and Artiria Medical have teamed up to speed up the development of a technology that could help stroke patients live longer and have a better quality of life.


Artiria, a medical device business, has developed a new technology that could help prevent arterial constriction following a hemorrhagic stroke.


Report Overview


The research contains in-depth information on the industry from the major competitors. It provides in-depth information on profitable growing markets as well as an analysis of market penetration across mature categories. It also includes thorough information on underserved locations, recent advancements, and investment opportunities. The study examines market shares, products, drivers, restraints, and main players in-depth. It gives information about upcoming technologies and game-changing product breakthroughs. The Market will stimulate market growth, as well as an increase in awareness about therapy and mechanical advances, as well as the rapid acceptance of newer definitions and measurement frameworks, among other factors driving the Cerebral Vasospasm Market.



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   5.4% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Headsense Medical Ltd (Israel), B. Braun Melsungen AG (Germany), Minnetronix, Inc (US), Bristol-Myers Squibb Company (US), Boehringer Ingelheim GmbH (Germany) and H. Lundbeck A/S (Denmark), Actelion Pharmaceuticals Ltd, GE Healthcare, Edge Therapeutics, Inc, SIEMENS AG, Koninklijke Philips N.V,
  Key Market Opportunities

  • Increasing hypertension among the population
  • Rising adoption of smoking and changing lifestyl
  •   Key Market Drivers

  • Increasing prevalence of subarachnoid hemorrhage
  • Risin prevalence of traumatic brain injury


  • Speak to Analyst Ask for Customization